Revenue up 5%: is this small-cap company a stock to buy?

Consistent progress from the business behind this stock makes it look like one to consider now as a buy for the long term.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Abstract bull climbing indicators on stock chart

Image source: Getty Images

I reckon there’s a bright future for FTSE SmallCap stock Porvair (LSE: PRV), but is it one to buy now? Well, it’s certainly on my focus list.

I like the firm’s long-term record of steady operational progress. Over the past 10 years, revenue’s notched up a compound annual growth rate (CAGR) of 6% and adjusted earnings per share of 10%.

They’re not the kind of exciting numbers that raise pulses to dangerous levels. However, the financial and trading record shows consistent improvement. In short, the stock looks a decent candidate to consider for a long-term investment.

Porvair operates in the specialist filtration, laboratory and environmental technology sectors. The directors aim to focus on markets with long-term growth potential. On top of that, the company seeks to serve areas where “product use is mandated and replacement demand is regular”.

Well-financed organic and acquisitive growth

I reckon that approach might be one of the key drivers behind the firm’s consistent growth and trading over the past few years.

Porvair’s operating segments are Aerospace & Industrial, Laboratory and Metal Melt Quality, all of which the directors insist have “clear” long-term growth drivers. Meanwhile, the progress of the overall business has been both organic and via acquisitions. So I’d expect more of the same ahead.

Today’s (1 July) interim results statement shows year-on-year revenue grew by 5% in the six months to 31 May. Although at constant currency rates, the rise was 8%.

However, currency adjusted underlying sales revenue actually fell by 3%. The overall rise occured because of the effects of prior acquisitions.

That weakness in like-for-like performance was caused by softening in the industrial and laboratory consumables markets. There was a trend among customers of reducing inventory levels “and more normal lead times through 2023 and 2024”.

De-stocking combined with adverse currency exchange rates to cause the firm’s profit margins to drop a bit too.

The situation demonstrates that Porvair’s operations are sensitive to general economic and cyclical influences. So the growth trajectory here’s unlikely to ever be straight up. As with most businesses, we could see volatility for operations and the stock over the coming years.

It’s one of the risks here and has the potential to cause a losing investment for shareholders. The directors said today that Inconsistency in trading patterns across the Group is not unusual”.

Anticipating a strengthening second half

Nevertheless, the company expects underlying market growth to return during the second half of the trading year. On top of that, the long-term growth drivers of Porvair’s operating sectors are robust. And chief executive Ben Stocks said the business looks set to move into 2025 “in good shape”.

City analysts anticipate mid-single-digit percentage advances for earnings and the dividend next year. Set against those estimates and with the share price near 668p, the forward-looking earnings multiple is just below 17. And the anticipated dividend yield’s a little under 1%.

That’s not the cheapest valuation in the world. But the balance sheet looks strong and multi-year trading performance has been consistent overall. I’d dive in with deeper research, then watch this one with a view to considering the stock on market dips and down-days.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has recommended Porvair Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Housing development near Dunstable, UK
Investing Articles

With its 6.5% dividend yield, is ITV a buy for my Stocks and Shares ISA?

ITV's dividend yield is almost twice as high as the FTSE 250 index average. Does this make it a no-brainer…

Read more »

Stacks of coins
Investing Articles

I’m targeting £15,401 in yearly dividends from £20,000 in this FTSE passive income heavyweight

Analysts expect this FTSE 100 gem to keep increasing dividends and generating strong earnings growth. So can it keep turbocharging…

Read more »

Array of piggy banks in saturated colours on high colour contrast background
Investing Articles

5%+ dividend yields and P/Es below 11! 2 FTSE 100 shares to consider

The London stock market's bursting with bargains following recent choppiness. Here Royston Wild reveals two cheap FTSE stars that deserve…

Read more »

Diverse group of friends cheering sport at bar together
Investing Articles

8%+ yields! 2 investment trusts to target a £1,640 passive income this new ISA year

Considering these investment trusts could put ISA investors on the fast-track to a large and reliable long-term passive income. Royston…

Read more »

Two female adult friends walking through the city streets at Christmas. They are talking and smiling as they do some Christmas shopping.
Investing Articles

Looking for ISA bargains? 4 FTSE 250 value stars to consider

Just like Warren Buffett, I love snapping up quality stocks when they're marked down in price. Here are four top…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

£20,000 invested in AstraZeneca shares 5 years ago is now worth…

AstraZeneca shares have more than doubled since 2021 -- but they still look very undervalued. Here’s why forecast earnings growth…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

£10,000 invested in Micron stock six months ago is now worth…

Dr James Fox talks about Micron stock -- one of his best investments over the past six months. Does he…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

100%+ earnings growth and a P/E of 8.5? Could this be a once-in-a-decade stock market gift for value investors?

As the UK stock market makes a go at a recovery, Mark Hartley identifies one FTSE 250 stock that could…

Read more »